All World

NicOx is closing its offices in the U.S.

The French biotechnology company NicOx plaice luggage United States after facing the U.S. health authorities' refusal to authorize the marketing of its flagship product, Naproxcinod.

The group based in Sophia Antipolis announced Thursday in a statement it was closing its offices on U.S. soil. The group currently employs 22 people at its facility in Warren, State of New Jersey, on a total of 127 employees. NicOx activities in the United States are on the marketing of Naxproxcinod and conducting clinical trials.

"It is with great regret that we must stop our operations in the United States," said the CEO of NicOx, Michele Garufi.Affirming its recognition for its employees, he adds that "it is essential to manage our resources as efficiently as possible."

NicOx announces however it incurs "the earliest" further discussions with the Federal Drug Administration (FDA), the federal drug agency. The biotechnology company remains hopeful of a successful marketing U.S. Naproxcinod, a drug on which he bet big. NicOx also said he will pursue the regulatory process in Europe.

Moreover, the biotech said it "will actively seek partnership agreements for Naproxcinod in Europe and the rest of the world, as well as other compounds of the portfolio. She finally announced it would study "parallel opportunities to take appropriate licensing and mergers and acquisitions.